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Abstract
OBJECTIVE: The objective of this study is to assess lymphotropic nanoparticle–enhanced magnetic resonance
imaging (LNMRI) in identifying malignant nodal involvement in patients with pancreatic ductal adenocarcinoma.
METHODS: Magnetic resonance imaging was performed in 13 patients with known or high index of suspicion of
pancreatic cancer and who were scheduled for surgical resection. Protocols included T2*-weighted imaging before
and after administration of Ferumoxytol (Feraheme) for the evaluation of lymph node involvement. Eleven of the
13 patients underwent a Whipple procedure and lymph node dissection. Nodes that lacked contrast uptake were
deemed malignant, and those that demonstrated homogeneous uptake were deemed benign. RESULTS: A total of
264 lymph nodes were resection, of which 17 were malignant. The sensitivity and specificity of LNMRI was 76.5%
and 98.4% at a nodal level and 83.3% and 80% at a patient level. CONCLUSION: LNMRI demonstrated high sensitivity
and specificity in patients with pancreatic ductal adenocarcinoma.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause
of cancer deaths in the United States. In 2013, it is estimated that a
total of 45,220 patients will be diagnosed with pancreatic cancer and
38,460 will die of this disease in the United States [1]. Surgical resection
through pancreatectomy remains the most viable curative option de-
spite inroads into better understanding of the molecular biology of
PDAC [2], emergence of targeted drugs [3,4], intensity-modulated
radiotherapy [5–7], and neoadjuvant chemotherapy regimen [8,9].
In parallel, advanced imaging methods including high-resolution com-
puted tomography (CT) scanning, magnetic resonance imaging (MRI),
positron emission tomography (PET), and ultrasound have contributed
to selecting patients for surgery while minimizing unnecessary surgeries.
One area where the new technologies have had less impact is with
minimal disease that has spread to locoregional lymph nodes. This
is not entirely surprising given the relatively low spatial resolution
and limited tissue characterization of clinical imaging tools. One way
to improve detection levels is by using radiotracers with high affinity
for cancer cells and lack of distribution to normal surrounding tissues.
This strategy has been successful for certain types of cancers [10]
but unfortunately not for PDAC. The reasons are multifactorial but
include extensive stromal components [11–13] and the lack of uni-
formly expressed biomarkers [14]. An alternative strategy to detect
nodal disease has been to target host cells in lymph nodes, for example,
by targeting nodal macrophages [15]. However, these previously tested
magnetic nanomaterials have been discontinued and were never studied
in PDAC.
One of the initial studies on lymphotropic nanoparticle–enhanced
MRI (LNMRI) was performed on 80 patients with prostate cancer
and found that the sensitivity of LNMRI was 90.5%, which was
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significantly higher than that of conventional MRI (sensitivity,
35.4%) [15]. Similar improved sensitivities in identifying malignant
lymph nodes were found in many other malignancies such as gastric
cancer [16], breast cancer [17], and endometrial and cervical cancers
[18]. More recently, the role of LNMRI in the management of
cerebrovascular lesions is under investigation. A recent study con-
cluded that intracranial aneurysms with early uptake of ferumoxytol
on MRI, and thus detecting the activity of macrophages in the
aneurysm walls, were prone to rupture and thus may warrant early
operative intervention [19]. Furthermore, LNMRI may also have a
role to play in imaging aspirin effect on macrophages localized in
the wall of the cerebral aneurysm [20].
The goal of the current study was to prospectively test a recently
Food and Drug Administration (FDA)–approved nanoparticle devel-
oped for iron replacement therapy, Ferumoxytol (Feraheme; AMAG
Pharmaceuticals, Lexington, MA), which has residual magnetic prop-
erties to be detectable by MRI. The long-circulating carboxymethyl
dextran–coated iron oxide ((FeO)1 − n(Fe2O3)n) nanoparticle slowly
extravasates, is thus delivered to lymph nodes by lymphatics, and is
internalized into macrophages, presumably through macropinocytosis.
We hypothesized that disturbances in lymph flow or in nodal architec-
ture caused by metastases lead to abnormal nanoparticle accumulation
patterns, detectable by MRI. We therefore performed a prospective
phase 2 study to determine the efficacy of the nanoparticle-enhanced
MRI approach. We enrolled patients with biopsy-proven PDAC
undergoing surgery and compared preoperative MRI appearance of
lymph nodes to histopathologic analyses.
Materials and Methods
Subjects
This exploratory study was performed as a prospective, single-
dose pilot study and was approved by the Institutional Review Board.
All patients with known or high index of suspicion of pancreatic
cancer and who were scheduled for surgical resection were eligible
for enrollment in this study. Patients underwent a CT of the chest,
abdomen, and pelvis before enrollment to exclude distant metas-
tases. Other entry criteria included the following: age > 18 and no
evidence of iron overload. Subjects with a known iron allergy were
also excluded.
The study group consisted of 13 patients (6 males and 7 females)
with a mean age of 64 years, range 40 to 91 years. Patient character-
istics are summarized in Table 1. Five patients underwent preoperative
chemoradiation. Eleven patients underwent surgery with an average of
23 lymph nodes resected, range 7 to 42. In total, 264 lymph nodes
were resected and available for analysis. In two patients, liver metas-
tases were identified on the preoperative LNMRI, and therefore, they
did not undergo resection.
Study Procedure
Nanoparticle. Ferumoxytol (Feraheme; AMAG Pharmaceuticals) is a
newer FDA-approved USPIO with a particle size of 17 to 31 nm and a
molecular weight of 731 kDa. It comprises a nonstoichiometric mag-
netite core of approximately 6.8 nm in diameter, and to protect the bio-
active iron, a semisynthetic carbohydrate coating of polyglucose sorbitol
carboxymethyl dextran covers it. Ferumoxytol is approved for human
use in the United States by the FDA for the treatment of iron deficiency
anemia in adults with chronic renal disease and is available as a sterile
neutral liquid providing a total of 510 mg of elemental iron in 17 ml.
All subjects received ferumoxytol IV in a calculated dose of 6 mg/
kg of body weight with a maximum dose of 510 mg. The decision
to inject 6 mg/kg was based on a prior study where 4 mg/kg was
injected. However, the degree of uptake in normal nodes was less
pronounced compared to an earlier nanoparticle, ferumoxtran-10
[21]; 6 mg/kg is a higher dose than in the prior study but less than
the therapeutic dose, which is 8 mg/kg.
Magnetic resonance imaging. MRI of the upper abdomen (T1-,
T2-, and T2*-weighted sequences) was performed on a 3T system
(Siemens, Erlangen, Germany) using an eight-channel phased array
coil. Ten patients underwent MRI before, immediately after, and
48 hours after the IV administration of ferumoxytol, whereas three
patients only had imaging 48 hours after the IV administration of
ferumoxytol. Quantitative T2* sequences were performed as breath-
hold, monopolar, multiecho, gradient echo sequences with six in-phase,
equally spaced echoes [echo time (TE) = 2.5-14.8 ms; repetition time
(TR) = 169 ms; thickness = 4 mm] in all patients. Imaging time ranged
from 35 to 45 minutes.
Image Analysis
The gradient echo (GRE) T2*-weighted sequences were reviewed
by a radiologist before the patient underwent surgery. The reviewer
used established diagnostic guidelines for subjective nodal character-
ization as outlined in an article by Saksena et al. [22]. Nodes were
considered involved with metastatic disease if greater than 50% of
the node has an area of high signal intensity on the post-contrast
images, based on visual inspection.
Signal-to-noise ratios (SNRs) of the lymph nodes were determined
on T2*-weighted images by placing operator-defined region of interest.
SNR was determined by dividing the mean signal intensity of a lymph
node by the SD of background noise. The paired Student’s t test was
used to evaluate the statistical difference between benign and malig-
nant lymph nodes before and after administration of ferumoxytol.
Surgery and Pathologic Analyses
When reviewing the MRI images, lymph node location was divided
into six regions: 1, porta hepatis; 2, posterior to pancreas; 3, anterior
Table 1. Overview of Population.
Patient Characteristics (N = 13)








Chronic pancreatitis 1 (8%)
Serous cystadenoma 1 (8%)
Neuroendocrine tumor 1 (8%)





IPNM indicates intraductal papillary mucinous neoplasia; TNM, TNM (tumor, lymph node,
metastasis) classification.
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to pancreas; 4, along superior mesenteric vein; 5, along celiac axis
and superior mesenteric artery; and 6, other. Before surgery, the im-
aging findings were discussed with the surgeon in case the lymph node
dissection had to be extended to include nodes that were positive
on the nanoparticle-enhanced MRI and would normally be beyond
the dissection.
Following resection, the pathologic and imaging findings were
compared on a regional basis. If the number of pathologically in-
volved lymph nodes in a region correlated with the number of nodes
considered positive on the nanoparticle-enhanced MRI, they were
considered as true positives. Conversely, if there were only benign
lymph nodes identified in any region on pathology and there were
no lymph nodes considered positive on nanoparticle-enhanced
MRI in the same region, all lymph nodes identified on MRI
were considered true negatives. If there was discordance between
the numbers of positive lymph nodes on nanoparticle-enhanced
Table 2. Patient Characteristics.
Nodes
Subject Preoperative Diagnosis Surgery Postoperative Diagnosis Total Benign Malignant
1 PDAC Yes PDAC 16 13 3
2 PDAC Yes PDAC 17 16 1
3 PDAC Yes Chronic pancreatitis 24 24 0
4 PDAC Yes IPMN 7 7 0
5 PDAC Yes PDAC 28 27 1
6 PDAC Yes PDAC 20 17 3
7 PDAC Yes PDAC 38 37 1
8 PDAC Yes IPMN 26 26 0
9 PDAC Yes PDAC 28 28 0
10 PDAC Yes PDAC 42 34 8
11 PDAC Yes Serous cystadenoma 18 18 0
12 PDAC No Neuroendocrine
13 PDAC No PDAC
Figure 1. Scatter plot comparing the SNR of benign and malignant
lymph nodes before and after the administration of ferumoxytol.
Figure 2. Benign lymph node. (A) Axial contrast-enhanced CT image shows a subcentimeter posterior pancreatic node (arrow). (B) Axial
precontrast gradient-echo image shows a hyperintense portocaval node (arrow). (C) Forty-eight hours after ferumoxytol, the node
shows a dramatic reduction in signal intensity indicating benignity (arrow). (D) Subsequent pathologic evaluation shows normal lymph
node architecture.
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MRI and pathology in any region, they were considered either
false positive (positive on MRI but negative on pathology) or false
negative (negative on MRI but positive on pathology).
Statistics
Primary efficacy parameters such as sensitivity, specificity, negative
and positive predictive values, and accuracy were performed at nodal
and patient levels. A P value < .05 was considered significant.
Results
Ten patients received dual MRI scans before and 48 hours after bolus
IV administration of the nanoparticle solution, and three patients
only had an MRI 48 hours after administration of the nanoparticle
solution. All patients tolerated the procedure and injections well, and
there were no side effects. Table 1 summarizes the demographics.
The nanoparticle administration resulted in expected lower signal in
organs rich in phagocytic cells such as liver, spleen, and bone marrow.
Because of this profound change, two patients had unexpected liver
metastases revealed and which were not identified on the noncontrast
MRI scans. These patients were therefore not eligible for a subsequent
Whipple operation.
Eleven patients underwent a Whipple resection, and a total of
264 lymph nodes were resected, locoregionally mapped, and then
individually analyzed for metastases by histopathology (Table 2).
Of these analyzed nodes, 17 malignant lymph nodes were identified
(6.4%). The lymph nodes were not grossly enlarged and thus did
not meet size criteria for macrometastases [23]. The mean short-axis
diameter of benign nodes was 5.5 mm ± 1.5 (range, 3-8.9 mm),
and the mean short-axis diameter of malignant nodes was 4.1 mm ±
0.96 (range, 3.2-6.3 mm).
MRI showed the small lymph nodes in expected regions around
the pancreas. Similar as in liver and spleen, nodal signal intensity
decreased on IV administration of the magnetic nanoparticle. Figure 1
summarizes the signal intensities of benign and malignant lymph
nodes before and after the administration of ferumoxytol. On non-
contrast scans, benign and malignant nodes had similar SNR (P =
.777). Following IV administration of ferumoxytol, the SNR of be-
nign lymph nodes (10.17 ± 3.5) was much lower compared to the
SNR of malignant nodes (81.93 ± 8.5; P < .0001). Figures 2 and
3 summarize some of the typical imaging findings underlying the
quantitative measurements.
At a nodal level, the sensitivity and specificity of lymphotropic
nanoparticle–enhanced MRI was 76.5% and 98.4%, respectively.
At a patient level, the sensitivity and specificity were 83.3% and
80%, respectively. In one patient, a single node was incorrectly
called positive based on imaging findings, and in another patient, a
histologically proven metastatic node was not identified. Table 3
summarizes the statistics of nodal staging.
Discussion
In our study, LNMRI had a sensitivity and specificity of 83.3% and
80% at the patient level and 76.5% and 98.4% at the nodal level.
Conventional cross-sectional imaging (CT, MRI, and PET/CT)
has been found to have a sensitivity of 0% to 42% in nodal staging
of pancreatic cancer [24–26]. In our patient cohort using a 1-cm
short-axis diameter threshold, or even the more conservative 8-mm
threshold [23], none of the malignant nodes would have been
Table 3. Statistics of MRI.
Nanoparticle MRI
Nodal Level Patient Level
Sensitivity 76.47 (49.76-92.17) 83.33 (36.48-99.12)
Specificity 98.38 (95.62-99.48) 80 (29.87-98.94)
PPV 76.47 (49.76-92.17) 83.33 (36.48-99.12)
NPV 98.38 (95.62-99.48) 80 (29.87-98.94)
PPV indicates positive predictive value; NPV, negative predictive value.
Values are expressed as percentages, and those in parentheses represent 95% confidence interval.
Figure 3. Malignant lymph node. (A) Axial precontrast gradient-
echo image shows a hyperintense peripancreatic node (arrow).
(B) Forty-eight hours after ferumoxytol, the node shows no signal
change indicating malignant infiltration. (C) Subsequent pathologic
evaluation showed architectural distortion from malignant infiltra-
tion of pancreatic cancer.
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correctly characterized. With the administration of a lymphotropic
nanoparticle, the sensitivity increased from 0% to 76.5%. LNMRI
correctly identified five of six patients with pathology-proven lymph
node involvement. It failed to identify nodal involvement in one
patient in which there was a very small metastatic focus in one lymph
node (Figure 4). Alternatively, in the only case where LNMRI falsely
diagnosed lymph node involvement on pathologic review, it was
nodular extension of the primary tumor rather than an involved lymph
node (Figure 5).
It has been widely documented in the literature that lymph node
status is one of the most important independent prognostic factors
of survival, in particular, for resectable cases. Studies have found that
the number of positive lymph nodes [27,28], lymph node ratios
(number of lymph nodes involved to number of lymph nodes exam-
ined) [29–32], and site of lymph node metastases [33–36] may be
more powerful predictors of postoperative survival than simple lymph
node status (e.g., negative or positive). A recent surgical study has
found that the number of lymph nodes examined affects, albeit dif-
ferently, the prognostic accuracy of the number of positive nodes
and the lymph node ratio [37].
The ability to preoperatively identify metastatic lymph nodes and
their location in patients with PDAC would alter management in
these patients, possibly making an extended lymphadenectomy nec-
essary or systemic therapy a better treatment option. LNMRI may
also have a role to play in identifying appropriate patients to receive
neoadjuvant therapy and in guiding radiation therapy by mapping
complete nodal status. The ability to identify the presence of lymph
node metastases in various other malignancies, such as breast can-
cer and testicular cancer, is crucial for selecting the correct surgical
approach and for deciding whether chemotherapy, radiotherapy, or
neoadjuvant treatment should be given.
A limitation of our study is the small number of patients that under-
went surgery; although 13 patients were enrolled, only 11 underwent
surgery. However, a total of 264 lymph nodes were evaluated in
these patients, allowing for more robust evaluation of this imaging
technique. Because of the small number of malignant lymph nodes,
there might have been bias toward higher specificity. Another limita-
tion is that direct node-to-node comparison could not be made
between the MRI and the surgical specimen; however, the nodes at
each site were counted and characterized as benign and malignant
and compared with the MRI.
Our study has shown that nanoparticle-enhanced MRI is an
accurate and safe method for detecting nodal metastases in patients
with pancreatic cancer.
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Figure 5. There is a nodular area of high signal intensity (arrow)
adjacent to the pancreatic mass on the precontrast T2-weighted
image (A). This nodule did not change signal between the pre–
ferumoxytol administration and 48 hours post–ferumoxytol admin-
istration (B) and was therefore called a metastatic node. On
subsequent pathologic evaluation, this was found to be nodular
extension of the primary tumor.
Figure 4. (A) Axial gradient-echo image 48 hours after ferumoxytol
administration shows a posterior lymph node that has homo-
genously low signal (arrow) consistent with a negative lymph
node. (B) Subsequent pathologic evaluation found a small cluster
of malignant cells (arrow).
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